Company and Stock Identity

How Viz.ai Connects to the Public Market

Company structure
Private company
Market access
No direct public shares are available.
Research focus
Track the cleared indication behind each module, the care-coordination layer around it, alert burden, and evidence that faster notification changes treatment rather than only app activity.

Viz.ai is privately held.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Viz.ai ... Company source

Viz.ai says it reaches 2,000 hospitals after ten years

Viz.ai published a ten year milestone announcement on July 28, 2026 stating that it operates in 2,000 hospitals, covers 230 million patients and holds 13 FDA clearances. The company says it received the first FDA De Novo authorizations for AI computer aided triage software and for ECG-based cardiovascular management software, and that it was the first company to receive Medicare reimbursement for AI software through the New Technology Add-on Payment program. All of these figures and firsts are the company's own account. The announcement does not break the 13 clearances down into individual submissions.

Why it matters: For time-critical conditions, installed base is close to the whole product, because an algorithm that is not running at the hospital a stroke patient reaches does nothing. Two notes on the wording: a De Novo is granted or authorized rather than cleared, and the two terms are not interchangeable even when a company uses them loosely. The reimbursement claim is the more durable one, because being first through Medicare's add-on payment program left behind a route other imaging AI companies now follow.

... Viz.ai ... Company source

Viz.ai launches a pulmonary suite for COPD, lung nodules and clots

Viz.ai announced the Viz Pulmonary Suite on May 14, 2026, describing it as a combination of acute and chronic pulmonary workflows with context-aware patient summaries, guideline surfacing and tools for specific conditions. The named conditions are chronic obstructive pulmonary disease, lung nodules and pulmonary embolism. The announcement cites time to pulmonary embolism treatment falling from 1.75 days to 0.56 days, and problem figures including 55 to 65 percent of potential in-network referrals lost to health system leakage, nearly 50 percent of hospitalized COPD patients readmitted within 30 days, and up to 71 percent of clinically significant lung nodules going without appropriate follow up. The announcement states no FDA status for the suite itself.

Why it matters: The interesting move here is that this product is partly about keeping referrals inside the health system, and Viz.ai says so plainly by citing leakage rates alongside clinical ones. That makes it an easier sell to a chief financial officer than a pure triage tool, and it means a buyer should ask whether a recommendation is driven by clinical guidance or by network retention. No FDA status is stated for the suite, so each component's regulatory standing needs checking separately before anyone treats an on-screen prompt as a cleared finding.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Imaging AI, clinical science, mobile engineering, product, regulatory affairs, implementation, and health-system growth.

Qualification signal: Experience in acute care, imaging informatics, clinical validation, or regulated software is more useful than a broad AI certificate for work tied to urgent treatment.

Check current roles at Viz.ai. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

Viz.ai appears on 8 cleared products in the federal 510(k) record, across 3 device types.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources